Searched for
INSULIN R
Kiran Mazumdar-Shaw names niece Claire as successor, targets semaglutide push from FY28; debt cut to $1.1 billionBiocon's Executive Chairperson, Kiran Mazumdar-Shaw, outlined a five-year leadership transition with her niece, Claire Mazumdar, as success...- The alchemist of Bengaluru: Kiran Mazumdar-Shaw began from a garageKiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who b...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsOver the next few sessions, as the uncertainty caused by the Gulf war intensifies and makes you anxious, remember this: It is not the first...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsWhat is evident in the last few trading sessions is how the street is treating Q4 earnings numbers. If a company delivers in terms of numbe...
- With sights on huge gains, Biocon to scale up AI focusBiopharma major Biocon is significantly scaling up its adoption of artificial intelligence across its operations, from R&D to manufacturing...
- Stolen insulin warning: How a missing batch of India's widely prescribed drug could put diabetes patients at serious riskInsulin Theft News: A stolen consignment of Lantus SoloStar insulin has triggered a nationwide safety alert in India, with regulators warni...
- Have diabetes? A doctor says this common habit might be quietly harming your blood sugar levels.Many people with diabetes focus on food but forget water. Doctors say dehydration can quietly raise blood sugar levels and cause false high...
- Biocon in very unique position globally as a biosimilars leader: Kiran Mazumdar-ShawBiocon is entering a transformative phase, leveraging regulatory shifts in the US and a strong insulin and GLP-1 portfolio to accelerate gr...
- USFDA issues CRL for proposed biosimilar Insulin-R: BioconThe CRL cites additional data required in the BLA submission and an expectation of satisfactory implementation of a corrective and preventi...
- View Biocon in terms of core EBITDA as R&D is an integral part of our biz growth: Kiran Mazumdar Shaw“I just want to emphasise that Biocon Biologics or Biocon as a business must be viewed in terms of core EBITDA and not just on EBITDA becau...
- Biocon Biologics' arm gets USD 90 mn contract from Malaysian government for supply of insulinsBiocon Biologics, a part of Biocon Ltd, has created a Centre of Excellence (CoE) for insulins in Malaysia with end-to-end capabilities to m...
- Biocon Biologics' biosimilar human insulin gets backing from EMA expert panelThe EMA's Committee for Medicinal Products for Human Use (CHMP) opinion will be considered by the European Commission. "The European Commis...
- Market needs to look at Biocon as a bellwether stock: Kiran Mazumdar Shaw"The biggest problem is that investors do not want us to spend on R&D and R&D is a very integral part of our business."
- Biocon's corporate governance standards raise alarm among analystsResearch firm ESPIROTO SANTO Investment bank has questioned the accounting practise of Bangalore based biotechnology company Biocon.
- Biocon logs smart recovery in fourth quarterAfter the divestment of Axicorp and the snapping of its biosimilar insulin deal with Pfizer, the company was expected to post a subdued per...
- Biocon to invest upto Rs 200 crore in R&D, manufacturing this FY"I would say roughly Rs 150 to Rs 200 cr in total we will be investing this year between manufacturing and R&D," Shaw said.
- Very bullish on Glenmark: Aunali Rupani, ARM ResearchNext 5 years will see a big run up in all the pharma stocks in India especially R&D.
- Biotech cos eye global JVs for R&D pushThese initiatives are happening at a time when pharmaceutical companies, too, seem unable to find takers for their molecules in a challengi...
- Sanofi-Aventis to shore up diabetes bizEurope’s largest pharma company Sanofi-Aventis has decided to shore up its diabetes business in India
- Clinical trials for oral insulin to enter phase two: BioconAfter the success of its recomibant human insulin "Insugen", Biocon said clinical trials for the oral insulin would soon enter phase two.
Load More
